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abstract: Prokineticin 1 (PROK1) signalling via prokineticin receptor 1 (PROKR1) regulates the expression of several genes with impor-
tant roles in endometrial receptivity and implantation. This study investigated PROK1 regulation of Dickkopf 1 (DKK1) expression, a negative
regulator of canonical Wnt signalling, and its function in the non-pregnant endometrium and ﬁrst trimester decidua. DKK1 mRNA expression
is elevated during the mid-secretory phase of the menstrual cycle and expression increases further in ﬁrst trimester decidua. DKK1 protein
expression is localized to glandular epithelial and stromal cells during the proliferative, early- and mid-secretory phases, whereas expression is
conﬁned to the stroma in the late-secretory phase and ﬁrst trimester decidua. PROK1 induces the expression of DKK1 in endometrial epi-
thelial cells stably expressing PROKR1 and in ﬁrst trimester decidua explants, via a Gq-calcium-calcineurin-nuclear factor of activated T-cells-
mediated pathway. Endometrial epithelial cell proliferation is negatively regulated by PROK1-PROKR1 signalling. We demonstrate that this
effect on cell proliferation occurs via DKK1 expression, as siRNA targeted against DKK1 reduces the PROK1-induced decrease in prolifer-
ation. Furthermore, decidualization of primary human endometrial stromal cells with progesterone and cyclic adenosine monophosphate is
inhibited by miRNA knock down of PROK1 or DKK1. These data demonstrate important roles for PROK1 and DKK1 during endometrial
receptivity and early pregnancy, which include regulation of endometrial cell proliferation and decidualization.
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Introduction
Prokineticin 1 (PROK1) is a secreted protein previously known as
endocrine gland vascular endothelial growth factor (LeCouter et al.,
2001; Li et al., 2001). PROK1 can regulate diverse biological processes
including intestinal smooth muscle contraction (Li et al., 2001), endo-
thelial cell proliferation and angiogenesis (LeCouter et al., 2001; Lin
et al., 2002), haematopoiesis (LeCouter et al., 2004; Dorsch et al.,
2005) and inﬂammation (Monnier and Samson, 2008). PROK1 binds
to two closely related G protein-coupled receptors, prokineticin
receptors 1 and 2 (PROKR1 and 2), and can mediate downstream
activation of several signalling molecules including extracellular signal-
regulated kinase 1/2 (Evans et al., 2008) and the calcineurin-nuclear
factor of activated T-cells (NFAT) pathway (Maldonado-Perez et al.,
2009). PROK1 is recognized as an important regulator of female
reproductive function (Maldonado-Perez et al., 2007), with described
roles in the ovary (Ferrara et al., 2003; Fraser et al., 2005), fallopian
tube (Shaw et al., 2010), placenta (Hoffmann et al., 2006; Denison
et al., 2008) and uterus (Battersby et al., 2004; Ngan et al., 2006;
Evans et al., 2008; Evans et al., 2009).
PROK1 in the non-pregnant endometrium is temporally regulated
across the menstrual cycle, with levels increasing in the mid-secretory
phase (Battersby et al., 2004; Evans et al., 2008). In addition, levels of
PROK1 and PROKR1 are further elevated in decidua of early preg-
nancy (Evans et al., 2008). Expression of PROK1 and PROKR1 is loca-
lized to glandular epithelial cells and the stroma throughout the
menstrual cycle and in decidua of early pregnancy (Battersby et al.,
2004; Evans et al., 2008). Studies have demonstrated regulation of
PROK1 by progesterone and human chorionic gonadotrophin in the
endometrium (Battersby et al., 2004; Ngan et al., 2006; Evans et al.,
2009). Furthermore, PROK1 signalling through PROKR1 in the endo-
metrium has been shown to regulate the expression of several genes
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cyclooxygenase 2 (Evans et al., 2008), leukaemia inhibitory factor
(Evans et al., 2009), interleukin 8 (IL8) (Maldonado-Perez et al.,
2009), interleukin 11 (IL11) (Cook et al., 2010) and connective
tissue growth factor (Waddell et al., 2010). These ﬁndings implicate
PROK1 as an important regulator of early pregnancy. Indeed, there
is a correlation between recurrent miscarriage and genetic polymorph-
isms in PROK1 and its receptors (Su et al., 2010). Aberrant elevation
in PROK1 expression has also been associated with impaired decidua-
lization and recurrent miscarriage (Salker et al., 2010).
We previously identiﬁed Dickkopf 1 (DKK1), a secreted antagonist
of the canonical Wnt signalling pathway (Baﬁco et al., 2001; Mao et al.,
2001; Semenov et al., 2001), as a target of PROK1-PROKR1 signalling
(Evans et al., 2008). Wnt signalling is considered to play a role in reg-
ulating proliferation (Hou et al., 2004; Jeong et al., 2009) and decidua-
lization (Li et al., 2007; Jeong et al., 2009) of the endometrium, and in
embryo2endometrial cross talk during implantation (Chen et al.,
2009). DKK1 expression is temporally regulated across the menstrual
cycle, with levels peaking in the mid-secretory phase (Carson et al.,
2002; Kao et al., 2002; Borthwick et al., 2003; Riesewijk et al.,
2003; Tulac et al., 2003; Horcajadas et al., 2004; Talbi et al., 2006),
and increases in response to decidualization in vitro (Kao et al.,
2002; Tulac et al., 2006; Kane et al., 2008).
Thus, this study investigated the effect of PROK1 on DKK1
expression and the role of the PROK1-DKK1 pathway in endometrial
function. Our data demonstrate that PROK1 and DKK1 regulate
endometrial processes including epithelial cellular proliferation and
differentiation of the stroma during early pregnancy.
Materials and Methods
Reagents
DMEM/F-12 GlutaMAX and RPMI 1640 culture media were obtained
from Invitrogen (Paisley, UK). G418 was obtained from InvivoGen (San
Diego, CA, USA). Recombinant PROK1 was purchased from Peprotech
(London, UK). Medroxyprogesterone acetate (MPA), cyclic adenosine
monophosphate (cAMP), ethylene glycol tetra-acetic acid (EGTA; extra-
cellular calcium chelator, used at 1.5 mM), collagenase and DNAse were
purchased from Sigma (Poole, UK). YM-254890 (Gq inhibitor, used at
1 mM) was kindly supplied by Dr Jun Takasaki (Molecular Medicine Lab-
oratories, Yamanouchi Pharmaceutical Co. Ltd, Tokyo, Japan).
Bapta-AM (intra-cellular calcium chelator, used at 50 mM), cyclosporin A
(CSA; calcineurin inhibitor, used at 1 mM) and Inhibitor of NFAT-
Calcineurin Association-6 (INCA-6, used at 40 mM) were purchased
from Calbiochem (Nottingham, UK). SN50 (nuclear factor-kB (NFkB)
cell-permeable inhibitory peptide, used at 100 mg/ml) was obtained
from Biomol International (Exeter, UK). The speciﬁc doses of the inhibi-
tors used were established previously (Sales et al., 2009). DKK1 mono-
clonal antibody (M11, clone 2A5) and recombinant protein were
purchased from Abnova Corp. (Taipei, Taiwan).
Tissue collection
Endometrial tissue was collected from women aged 21–39 with no
underlying endometrial pathology and regular menstrual cycles (25–35
days) who had not received any hormonal preparation for 3 months
preceding biopsy collection. Biopsies were dated according to Noyes cri-
teria by a pathologist. Circulating oestradiol and progesterone concen-
trations were measured and were consistent with the histological
assessment. First trimester decidua tissue (7–10 weeks gestation) was
collected from women undergoing elective surgical termination of preg-
nancy with gestation conﬁrmed by ultra-sound scan. Ethical approval was
obtained from Lothian Ethics Research Committee, and written
informed consent obtained before tissue collection.
Cell and tissue culture and treatment
Stable PROKR1 expressing Ishikawa cells were produced and character-
ized as described (Evans et al., 2008). PROKR1 Ishikawa cells were cul-
tured in DMEM/F-12 culture medium supplemented with 10% foetal
bovine serum, 100 IU penicillin and 100 mg streptomycin at 378C and
5% CO2, with addition of 200 mg/ml G418. Decidua tissue for explant
studies was chopped ﬁnely, maintained in serum-free DMEM/F-12
medium and divided into equal portions for experimental procedures.
Cells and tissue were incubated overnight in serum-free medium before
treatment with 40 nM PROK1. In signalling pathway inhibitor experiments,
cells or tissue were pre-treated with inhibitors for 1 h before the addition
of PROK1. Regulator of calcineurin 1 isoform 4 (RCAN1-4) adenovirus
was produced as described (Maldonado-Perez et al., 2009). Ishikawa
PROKR1 cells were incubated with ﬁve adenovirus plaque-forming units
(pfu)/cell for 24 h to induce over-expression of RCAN1-4, and then
serum-starved overnight before treatment with 40 nM PROK1 for 8 h.
Decidua explants were incubated with 2.5 × 10
6 adenovirus pfu/piece
of tissue (5 pfu/cell, estimating 5 × 10
5 cells/piece of tissue) for 24 h,
and then treated with 40 nM PROK1 for 24 h. Cells and tissue were
harvested with conditioned medium collected for enzyme-linked immuno-
sorbent assay (ELISA) and RNA extracted for reverse transcriptase-
polymerase chain reaction (RT–PCR) analysis.
Primary human endometrial stromal cell
isolation, transduction and decidualization
Non-pregnant endometrial tissue was digested in a solution of 1 mg/ml
collagenase and 0.1 mg/ml DNAse in 2 ml phosphate-buffered saline
(PBS) for 80 min at 378C. Tissue was further dissociated by passing
through an 18 G needle, and after addition of 10 ml RPMI culture
medium supplemented with 10% fetal bovine serum, 100 IU penicillin
and 100 mg streptomycin, was passed through a 70 mm ﬁlter. The resulting
ﬁltrate containing stromal cells was centrifuged at 1700g for 3 min and
resuspended in 10 ml complete RPMI medium and plated in a 75 cm
2
tissue culture ﬂask.
Lentiviral miRNA constructs were used to knock down the
expression of PROK1 or DKK1 in primary stromal cells. Cells were
transduced with Lv-cppt-EmGFP-PROK1-72_287 (emerald green ﬂuor-
escent protein (GFP) denoted by EmGFP), which targets two regions
of PROK1 (Evans et al., 2009), or two separate miRNA sequences
targeting DKK1 (Lv-cppt-EmGFP-DKK1-92 or -DKK1-487), at ﬁve trans-
duction units/cell. All numbers correspond to annealing site in basepairs
downstream of the start codon. Oligonucleotides encoding DKK1
miRNA constructs were obtained from Invitrogen and inserted
into the pcDNA6.2-GW/EmGFP-miR vector. These were
recombined to create pLenti6/V5-cppt-EmGFP-hum-DKK1-92 and
-487. Lentivirus was produced with a Block-iT lentiviral Pol II miR
RNAi expression system (Invitrogen) according to the manufacturer’s
instructions.
In decidualization experiments, cells were treated with 1 mM MPA and
0.2 mg/ml cAMP in RPMI supplemented with 2% foetal bovine serum and
antibiotics for 5 days. The medium was refreshed every 2 days. Cells were
harvested with RNA extracted for RT–PCR analysis.
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Total RNA was extracted from cells using QIAzol lysis reagent and MaX-
tract phase lock tubes from Qiagen (Crawley, UK), according to the man-
ufacturer’s guidelines. Total RNA was extracted from tissue using the
RNeasy mini kit from Qiagen. RNA samples were quantiﬁed and
reverse transcribed using the SuperScript VILO cDNA synthesis kit from
Invitrogen. PCR reactions were carried out using an Applied Biosystems
ABI 7500 system. Primer and FAM (6-carboxyﬂuorescein)-labelled probe
sequences are listed in Table I and were designed to span an intron.
The expression of analysed genes was normalized for RNA loading using
18S ribosomal RNA primers and probe (Applied Biosystems, UK).
Results were calculated relative to a standard included in all plates (endo-
metrial tissue cDNA). Tissue DKK1 expression levels are shown as relative
to the endometrial tissue cDNA standard, and experimental data are
expressed as fold increase compared with vehicle-treated control cells
or tissue.
Enzyme-linked immunosorbent assay
Conditioned medium was assayed for DKK1 using an ELISA kit from R&D
Systems (Abingdon, UK), according to the manufacturer’s instructions.
Brieﬂy, medium or standards were applied to a microplate coated with
mouse anti-human DKK1 antibody for 2 h at room temperature. Biotiny-
lated goat anti-human DKK1 antibody was then applied for 2 h, followed
by streptavidin-horseradish peroxidise (HRP) for 20 min. A colour devel-
opment solution (1:1 mix of hydrogen peroxide and tetramethylbezidine)
was applied for 20 min and colour development stopped by addition of
sulphuric acid. The optical density was measured at 450 nm and DKK1
levels in pg/ml were calculated from a standard curve.
Immunohistochemistry
Localization of DKK1 was performed by immunohistochemistry in 5 mm
parafﬁn-embedded sections. Brieﬂy, sections were dewaxed and then
rehydrated, and antigen retrieval was performed by boiling in 0.01 M
citrate buffer for 20 min. Endogenous peroxidise activity was quenched
using 3% H2O2/PBS for 30 min at room temperature and non-speciﬁc
protein binding was blocked using 20% normal goat serum. Sections
were incubated with mouse anti-human DKK1 monoclonal antibody
(3 mg/ml) overnight at 48C. A goat anti-mouse biotinylated secondary
antibody was applied for 1 h at room temperature, followed by
streptavidin-HRP for 1 h. HRP activity was detected by incubation with
diaminobenzidine for 5 min and the reaction was stopped in tap water.
Sections were then counterstained, dehydrated, cleared and mounted
before photographs were taken using a Zeiss AxioCam HRc coupled to
an Olympus AX70 microscope. Negative controls were performed using
primary antibody pre-absorbed with a 10 times excess of DKK1 protein
(30 mg/ml) overnight at 48C.
Proliferation assay
Transient transfections of PROKR1 Ishikawa cells were performed using
commercially supplied DKK1 targeting siRNA (Invitrogen) with Superfect
transfection reagent (Qiagen), according to the manufacturer’s instruc-
tions. For RCAN1-4 adenovirus over-expression studies, Ishikawa
PROKR1 cells were incubated with ﬁve adenovirus pfu/cell of either
control adenovirus or RCAN1-4 adenovirus for 24 h. Proliferation of
cells was then determined using a CellTitre 96 Aqueous One Solution
cell proliferation assay (Promega, Southampton, UK). Brieﬂy, cells were
seeded at 5 × 10
3 cells per well in a 96-well plate and serum-starved over-
night before treatment with 40 nM PROK1. After 72 h, proliferation was
measured by addition of the CellTitre 96 Aqueous One Solution
reagent, according to the manufacturer’s protocol. Cells were incubated
for 4 h at 378C and 5% CO2 to reduce the tetrazolium compound to a
490 nm absorbing formazan compound. Relative cell number is expressed
as the absorbance value measured at 490 nm.
Statistics
T-test was used for all paired analyses, two-way analysis of variance
(ANOVA) with Bonferroni post-hoc test for time course treatment ana-
lyses and one-way ANOVA with Tukey‘s post-hoc test for analysis of
three groups or more. Data are shown as mean+SEM.
Results
Expression and localization of DKK1 in the
human endometrium and ﬁrst trimester
decidua
We investigated the temporal expression of DKK1 mRNA across the
menstrual cycle and in decidua of early pregnancy using quantitative
RT–PCR analysis. DKK1 mRNA expression was signiﬁcantly elevated
in the mid-secretory phase of the menstrual cycle (mean fold change
328.6 compared with proliferative phase, Fig. 1A). DKK1 expression
was further elevated in ﬁrst trimester decidua tissue compared with
mid-secretory endometrium (mean fold change 2.9, Fig. 1A).
The localization of DKK1 protein was determined in human endo-
metrium and decidua by immunohistochemistry. DKK1 protein loca-
lized to the stromal compartment, blood vessels and glandular
epithelium in proliferative phase endometrium (Fig. 1B). In the early-
(Fig. 1C) and mid-secretory phases (Fig. 1D), DKK1 expression was
present in the stroma, and became restricted to the basal and baso-
lateral region of the glandular epithelium. In late-secretory phase
endometrium (Fig. 1E) and decidua tissue (Fig. 1F), DKK1 expression
was only seen in the stroma and blood vessels and was absent from
the glandular epithelium. Tissue sections incubated with primary anti-
body pre-absorbed with DKK1 protein was used as a negative control
(Fig. 1G).
........................................................................................
Table I Taqman primer and probe sequences for
DKK1, IGFBP1, PRL and IL11.
Gene Primer/probe sequence (5′–3′)
DKK1 forward GCGGGAATAAGTACCAGACCAT
DKK1 reverse GGGACTAGCGCAGTACTCATCAGT
DKK1 probe TACCAGCCGTACCCGTGCGCAG
IGFBP1 forward CACAGGAGACATCAGGAGAAGAAA
IGFBP1 reverse ACACTGTCTGCTGTGATAAAATCCAT
IGFBP1 probe TTCCAAATTTTACCTGCCAAACTGCAACAA
PRL forward CGGAAGTACGTGGTATGCAAGA
PRL reverse TCAGGATGAACCTGGCTGACT
PRL probe CCCCGGAGGCTATCCTATCCAAAGCT
IL11 forward CCCAGTTACCCAAGCATCCA
IL11 reverse AGACAGAGAACAGGGAATTAAATGTGT
IL11 probe CCCCAGCTCTCAGACAAATCGCCC
628 Macdonald et al.PROK1 increases DKK1 expression in
PROKR1 Ishikawa cells via the
calcineurin-NFAT pathway
We previously identiﬁed DKK1 as a target of PROK1-PROKR1 signal-
ling using microarray proﬁling (Evans et al., 2008). The expression
levels of DKK1 across the menstrual cycle and in early pregnancy
seen in the present study mirror the expression proﬁle of PROK1
reported previously (Evans et al., 2008). Therefore, we sought to
determine whether the observed DKK1 expression in endometrial
epithelial cells is induced by autocrine or paracrine PROK1 stimulation
as suggested by the reported PROK1 immunolocalization to both epi-
thelial and stromal cells. Studies were performed on an endometrial
epithelial cell line (Ishikawa) engineered to express levels of
Figure 1 Temporal expression and localization of DKK1 in the human endometrium and ﬁrst trimester decidua. DKK1 mRNA expression levels in
human endometrium across the menstrual cycle (Prolif; n ¼ 10, ES; n ¼ 10, MS; n ¼ 7, LS; n ¼ 4) and ﬁrst trimester decidua tissue (n ¼ 33) are shown
in (A). mRNA levels are expressed relative to a standard endometrial cDNA sample. Boxes represent data lying within the ﬁfth to the 95th percentile
and whiskers represent the minimum and maximum values. *, ** and *** represent signiﬁcance at P , 0.05, P , 0.01 and P , 0.001, respectively.
Localization of DKK1 protein across the menstrual cycle and during early pregnancy is shown (for each stage of the cycle and early pregnancy
three serial sections from 3–5 different tissue samples were examined, representative sections are shown in B–F). Expression in the glandular epi-
thelium (g) during the proliferative phase (B) became restricted to the basal and basolateral region of the glandular cells in the early- (C) and mid-
secretory (D) phases. In the late-secretory phase (E) and ﬁrst trimester decidua (F), expression was only present in the stroma (s) and blood vessels
(bv). Negative control (-ve) is shown for decidua tissue (G).
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(Evans et al., 2008). Treatment of PROKR1 Ishikawa cells with
40 nM PROK1 resulted in a time-dependent increase in DKK1
mRNA expression (Fig. 2A) and protein release into the culture
medium (Fig. 2B), which peaked at 6 h (P , 0.001 versus 0 h) and
24 h (P , 0.001 versus vehicle), respectively. The molecular mechan-
ism whereby PROK1 regulates DKK1 expression via PROKR1 was
investigated using a panel of small-molecule chemical inhibitors of
intracellular signalling (Fig. 2C). This indicated that PROK1-induced
DKK1 mRNA expression after 6 h of agonist stimulation was signiﬁ-
cantly inhibited by the use of a Gq inhibitor (YM254890; P ,
0.001), extra- and intra-cellular calcium chelators (EGTA and
Bapta-AM, respectively; P , 0.001), a calcineurin inhibitor (CSA; P
, 0.05) and an inhibitor of NFAT (INCA-6; P , 0.001). In contrast,
inhibition of NFkB (inhibitory peptide SN50), which shares an overlap-
ping consensus sequence with NFAT, had no effect on
PROK1-induced DKK1 mRNA expression. Calcineurin–NFAT signal-
ling induced by PROK1 is negatively regulated by regulator of calci-
neurin 1 isoform 4 (RCAN1-4) (Maldonado-Perez et al., 2009;
Cook et al., 2010). We investigated whether RCAN1-4 also acts as
a negative regulator of PROK1-induced DKK1 expression. Adenoviral
over-expression of RCAN1-4 in PROKR1 Ishikawa cells signiﬁcantly
decreased PROK1-induced DKK1 expression (P , 0.01 versus
control vector adenovirus, Fig. 2D). Collectively, these data demon-
strate a role for the calcineurin-NFAT pathway as a mediator of
PROK1-induced DKK1 mRNA expression in endometrial epithelial
cells.
PROK1 increases DKK1 expression in ﬁrst
trimester decidua tissue via the
calcineurin-NFAT pathway
In ﬁrst trimester decidua tissue, PROK1 and PROKR1 are expressed in
both the epithelial cells and stroma (Evans et al., 2008), although
DKK1 expression is conﬁned to the stromal compartment. We there-
fore investigated the molecular pathway whereby PROK1 regulates
DKK1 expression in decidualized stromal cells using ﬁrst trimester
decidua explants. Treatment of decidua tissue with 40 nM PROK1
caused a time-dependent increase in DKK1 mRNA expression (after
12 h P , 0.05 versus 0 h, Fig. 3A). PROK1-induced DKK1 expression
Figure 2 PROK1 induces the expression of DKK1 via the NFAT signalling pathway in PROKR1 Ishikawa cells. PROKR1 Ishikawa cells treated with
40 nM PROK1 over a 24 h time-course (n ¼ 10 for each time point) showed a signiﬁcant fold increase in DKK1 mRNA expression, which peaked at
6h( A). Treatment of PROKR1 Ishikawa cells with 40 nM PROK1 caused a signiﬁcant increase in the secretion of DKK1 protein into the culture
medium compared with vehicle-treated cells at 12 and 24 h (n ¼ 3 for each time point) (B). Induction of DKK1 mRNA expression at 6 h in
PROKR1 Ishikawa cells (n ¼ 17) was inhibited by the use of a Gq inhibitor (YM254890) (n ¼ 8), extra- (EGTA) (n ¼ 9) and intra-cellular
(Bapta-AM) (n ¼ 4) calcium chelators, a calcineurin inhibitor (CSA) (n ¼ 3) and a NFAT inhibitor (INCA-6) (n ¼ 10). An inhibitor of NFkB
(SN50) (n ¼ 3) did not reduce PROK1-induced DKK1 expression (C). PROKR1 Ishikawa cells infected with adenovirus (AdV) to over-express
RCAN1-4 (n ¼ 7) showed a signiﬁcant decrease in PROK1-induced DKK1 expression, when compared with cells infected with control vector
(Ctrl) AdV (n ¼ 7) (D). Data are mean+SEM of at least three independent experiments. *, ** and *** represent signiﬁcance at P , 0.05,
P , 0.01 and P , 0.001, respectively. Fold change was calculated by dividing expression levels in PROK1-treated cells by vehicle-treated control cells.
630 Macdonald et al.at 24 h was signiﬁcantly inhibited by the use of a Gq inhibitor
(YM254890; P , 0.05), extra- and intra-cellular calcium chelators
(EGTA; P , 0.01 and Bapta-AM; P , 0.001 respectively), a calcineurin
inhibitor (CSA; P , 0.001) and an inhibitor of NFAT (INCA-6; P ,
0.001, Fig. 3B). Furthermore, PROK1-induced DKK1 expression
was also inhibited by adenoviral over-expression of RCAN1-4 in
ﬁrst trimester decidua explants (P , 0.05 versus control vector ade-
novirus, Fig. 4C). These data indicate that DKK1 is regulated by
PROK1 via the Gq-calcium-calcineurin-NFAT pathway in decidualized
stromal cells.
PROK1-mediated DKK1 expression via the
NFAT pathway inhibits PROKR1 Ishikawa
cell proliferation
Wnt signalling has been proposed to stimulate cellular proliferation
during the menstrual cycle (Hou et al., 2004; Jeong et al., 2009;
Wang et al., 2009), and DKK1 is known to inhibit the proliferation
of epithelial cells in several tissue types, including the intestine (Pinto
Figure 3 PROK1 induces the expression of DKK1 via the NFAT
signalling pathway in cultured ﬁrst trimester decidua tissue. First tri-
mester decidua tissue treated with 40 nM PROK1 over a 24 h time-
course (n ¼ 9 for each time point) displayed a signiﬁcant fold increase
in DKK1 mRNA expression at 12 and 24 h (A). The increase in DKK1
mRNA expression at 24 h (n ¼ 5) was inhibited by the use of a Gq
inhibitor (YM254890) (n ¼ 3), extra- (EGTA) (n ¼ 4) and intra-
cellular (Bapta-AM) (n ¼ 5) calcium chelators, a calcineurin inhibitor
(CSA) (n ¼ 4) and a NFAT inhibitor (INCA-6) (n ¼ 4) (B). Transduc-
tion of decidua tissue with RCAN1-4 (n ¼ 5) adenovirus (AdV)
caused a signiﬁcant decrease in PROK1-induced DKK1 expression,
when compared with tissue infected with control vector (Ctrl) adeno-
virus (n ¼ 5) (C). Data are mean+SEM of at least ﬁve independent
experiments. *, ** and *** represent signiﬁcance at P , 0.05, P , 0.01
and P , 0.001 respectively. Fold change was calculated by dividing
expression levels in PROK1-treated tissue by vehicle-treated
control tissue.
Figure 4 PROK1 via the NFAT pathway regulates the proliferation
of PROKR1 Ishikawa cells. PROK1 caused a reduction in the prolifer-
ation of PROKR1 Ishikawa cells transfected with a negative control
(Ctrl) siRNA sequence after 72 h; transfection of DKK1 siRNA
before treatment with PROK1 prevented this reduction (A). Relative
cell number is expressed as fold change over control. RCAN1-4 ade-
novirus over-expression in PROKR1 Ishikawa cells (PROK1 + -
RCAN1-4 AdV) reduced the negative effect of PROK1 treatment
on proliferation compared with cells expressing control vector AdV
(PROK1 + Ctrl AdV) (B). Expression of RCAN1-4 (Vehicle + -
RCAN1-4 AdV) alone did not have an effect on proliferation com-
pared control (Vehicle + Ctrl AdV). Relative cell number is
expressed as the absorbance value measured at 490 nm. Data are
mean+SEM of three independent experiments, n ¼ 8 for each treat-
ment. *, ** and *** represent signiﬁcance at P , 0.05, P , 0.01 and
P , 0.001 respectively.
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(Osada et al., 2010). We hypothesized that one of the functional roles
of PROK1-induced DKK1 expression may be as a negative regulator of
endometrial epithelial cell proliferation. To examine this, we trans-
fected PROKR1 Ishikawa cells with scrambled control siRNA or
DKK1 targeting siRNA. We found that PROK1 reduced cellular pro-
liferation in PROKR1 Ishikawa cells transfected with a negative
control siRNA sequence (P , 0.05; Fig. 4A). Silencing DKK1
expression with siRNA prevented this PROK1-mediated reduction
in cellular proliferation (P , 0.01; Fig. 4A). To determine whether
the NFAT pathway mediates this effect we infected PROKR1 Ishikawa
cells with adenovirus over-expressing RCAN1-4, which inhibits the
translocation of NFAT to the nucleus. We found that expression of
RCAN1-4 reduced the negative effect of PROK1 on cellular prolifer-
ation in comparison to PROKR1 Ishikawa cells infected with control
vector adenovirus (P , 0.001; Fig. 4B). Expression of RCAN1-4
alone did not affect cellular proliferation (Fig. 4B).These data suggest
that PROK1 secreted by epithelial cells or sub-epithelial stromal
cells may induce DKK1 release via the NFAT pathway to negatively
regulate epithelial cell proliferation in the endometrium.
PROK1 and DKK1 expression inﬂuence
decidualization in human primary
endometrial stromal cells
In the current study, DKK1 expression was elevated in ﬁrst trimester
decidua tissue and immunohistochemistry localized DKK1 to the
stromal compartment, predominantly to the decidualized stromal
cells. We therefore investigated whether PROK1 and DKK1 regulate
the decidualization of endometrial stromal cells. Primary human endo-
metrial stromal cells were decidualized by treatment with cAMP and
progesterone for 5 days, which induced an increase in DKK1 mRNA
expression (P , 0.05, Fig. 5A) and protein release (P , 0.05,
Fig. 5B). Lentiviral delivery of miRNA sequences directed against
PROK1 (Lv-cppt-GFP-PROK1-72_287) (Evans et al., 2009) signiﬁ-
cantly reduced DKK1 mRNA expression (P , 0.05 versus negative
control sequence, Fig. 5A) and protein release (P , 0.05 versus nega-
tive control sequence, Fig. 5B) in decidualized endometrial stromal
cells, suggesting that PROK1 contributes to the induction of DKK1
expression during decidualization. Knock down of PROK1 expression
prior to decidualization signiﬁcantly decreased the expression of three
markers of decidualization, insulin-like growth factor 1 (IGFBP1; P ,
0.05 versus negative control sequence, Fig. 5C), prolactin (PRL; P ,
0.001 versus negative control sequence, Fig. 5D) and IL11 (P , 0.05
versus negative control sequence, Fig. 5E). Lentiviral knock down of
DKK1 (using Lv-cppt-GFP-DKK1-92 or -DKK1-487) prior to decidua-
lization also signiﬁcantly decreased the expression of IGFBP1, PRL and
IL11 (P , 0.05 versus negative control; Fig. 5C, D and E). We con-
ﬁrmed by ﬂuorescent microscopy that suppression of PROK1 or
DKK1 with lentiviral miRNA inhibited changes in cell morphology
associated with the decidualization response. When endometrial
stromal cells, which had been transduced with a negative control
miRNA sequence (Fig. 5F; Vehicle + Control), were treated with
cAMP and progesterone for 5 days they became more rounded and
cobble stone-like, indicative of decidualization (Fig. 5F; Dec +
Control). Transduction of endometrial stromal cells with either
PROK1 miRNA (Fig. 5F; Dec + PROK1-72_287) or DKK1 miRNA
(Fig. 5F; Dec + DKK1-92 or DKK1-487) prevented this alteration in
cellular morphology in response to the decidualizing stimulus.
Discussion
PROK1 is a secreted protein expressed in the receptive endometrium
and decidua of early pregnancy, which can regulate the expression of
numerous genes important in implantation and the establishment of
pregnancy (Evans et al., 2008). This study identiﬁed that PROK1 signal-
ling via PROKR1 can induce the expression of DKK1, an inhibitor of
canonical Wnt signalling. DKK1 acts by antagonizing the Wnt ligand
co-receptor low-density lipoprotein receptor-related protein 6
(LRP6) (Baﬁco et al., 2001; Mao et al., 2001; Semenov et al., 2001)
via the formation of a complex with LRP6 and receptors speciﬁc to
DKK1, Kremen 1 and Kremen 2 (Mao et al., 2002).
Wnt signalling has been demonstrated to be an important regulator
of proliferation, whereas switching off Wnt signalling permits the
occurrence of cellular differentiation (Reya and Clevers, 2005; Wang
et al., 2009). Wnt signalling has been suggested to contribute to the
regulation of endometrial development and differentiation during the
normal menstrual cycle (Tulac et al., 2003) and to the events of
early pregnancy (Chen et al., 2009; Sonderegger et al., 2010). The
ligands, receptors and inhibitors of the Wnt signalling family show
unique expression patterns and cellular localizations in the endome-
trium (Tulac et al., 2003). Evidence suggests that during the normal
menstrual cycle, Wnt signalling mediates endometrial proliferation
during the proliferative phase (Hou et al., 2004;, Jeong et al., 2009),
and that inhibition of Wnt signalling by up-regulation of DKK1
during the mid-secretory phase may allow differentiation of the
stroma (Tulac et al., 2006).
In this study, we have demonstrated a temporal pattern of DKK1
expression across the human menstrual cycle, conﬁrming previous
reports that DKK1 levels peak in the mid-secretory phase (Carson
et al., 2002; Kao et al., 2002; Borthwick et al., 2003; Riesewijk et al.,
2003; Tulac et al., 2003; Horcajadas et al., 2004; Talbi et al., 2006).
Furthermore, we show for the ﬁrst time that DKK1 expression is
further elevated in ﬁrst trimester decidua tissue. DKK1 protein
expression was observed in proliferative phase endometrium through-
out the stroma and glandular epithelium, which is in agreement with a
previous study by Yi et al. (2009). During the secretory phase of the
menstrual cycle, we observed strong stromal DKK1 expression, in
accordance with a study by Tulac et al. (2003). DKK1 localization in
the glands during the early- and mid-secretory phases of the menstrual
cycle became restricted to the basal and basolateral surfaces of the
epithelial cells. In late-secretory endometrium and ﬁrst trimester
decidua tissue, DKK1 protein expression was absent from the gland-
ular epithelial compartment, though present in stromal cells and
blood vessels.
This epithelial polarization and alteration in the cellular localization
of DKK1 expression across the menstrual cycle and during early preg-
nancy suggests that it may mediate the switch between cellular pro-
liferation and differentiation needed to promote maturation of the
glands and decidualization of the stroma during the secretory phase,
via the modulation of Wnt signalling. Indeed, Wnt signalling has
been shown to regulate cell polarity in the uterine epithelium during
embryonic development (Vandenberg and Sassoon, 2009). It may
be the case that DKK1 is expressed on the basal side of the glandular
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strual cycle to maintain cell polarity, or to promote differentiation as
the glands and stroma undergo secretory transformation. The
absence of DKK1 expression on the luminal surface of the glands
suggests it is not released into the glandular secretions. This would
prevent release into the uterine lumen and any potential harmful
effects of DKK1 on the developing blastocyst. Canonical Wnt signalling
has been shown to be important in promoting blastocyst activation
and competency for implantation (Xie et al., 2008).
Previously, PROK1 has been shown to regulate the expression of
IL8 (Maldonado-Perez et al., 2009) and IL11 (Cook et al., 2010) via
a Gq-calcium-calcineurin-NFAT signalling pathway. We have
Figure 5 PROK1 and DKK1 positively regulate decidualization of primary human endometrial stromal cells. Lentiviral delivery of a chained miRNA
construct to knock down PROK1 (PROK1-72_287) signiﬁcantly reduced DKK1 mRNA expression (A) and protein release (B) in primary human
endometrial stromal cells decidualized with 1 mM MPA and 0.2 mg/ml cAMP for 5 days (Dec + PROK1-72_287), when compared with cells trans-
duced with negative control miRNA (Dec + Ctrl). Lentiviral delivery of miRNA constructs to knock down PROK1 (PROK1-72_287) and DKK1
(DKK1-92 or DKK1-487) signiﬁcantly reduced expression of the markers of decidualization IGFBP1 (C), PRL (D) and IL11 (E) in primary human endo-
metrial stromal cells. Treatments n ¼ 5 in triplicate. Lentiviral GFP expression was used to compare cell morphology in decidualized cells (Dec) with or
without (Ctrl) miRNA sequences targeted to PROK1 or DKK1 (F). Decidualized stromal cells transduced with the negative control miRNA sequence
(Dec + Ctrl) appeared round in shape. Knock down of PROK1 or DKK1 inhibited this change in cell shape and cells remained spindle-like, similar to
undecidualized cells transduced with negative control miRNA (Vehicle + Ctrl). Data are mean+SEM of six experiments. *, ** and *** represent
signiﬁcance at P , 0.05, P , 0.01 and P , 0.001 respectively. Fold change was calculated by dividing expression levels in cells treated with a
decidualizing stimulus by vehicle-treated control cells.
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pathway in endometrial epithelial cells and decidualized stromal
cells. In this pathway, calcium-dependent activation of calcineurin
causes dephosphorylation of NFAT, allowing it to translocate to the
nucleus and activate NFAT-regulated gene transcription. The
calcinuerin-NFAT signalling pathway is regulated by RCAN1-4, an
endogenous negative feedback inhibitor which acts to bind to calci-
nuerin and prevent its activation of NFAT (Fuentes et al., 2000).
We have conﬁrmed that RCAN1-4 is a negative regulator of PROK1-
mediated DKK1 expression, similar to our observations for IL8
(Maldonado-Perez et al., 2009) and IL11 (Cook et al., 2010). There-
fore, the same signalling cascade is activated by PROK1 to control
DKK1 expression in epithelial cells to regulate proliferation, and in
the decidua to regulate decidualization of the stroma. The
calcineurin-NFAT pathway has previously been shown to be involved
in regulating endometrial epithelial cell proliferation (Wallace et al.,
2011), and in the endometrial expression of IL11, an important
mediator of decidualization (Cook et al., 2010).
Our results indicate that PROK1-induced DKK1 expression via the
NFAT pathway can negatively regulate the proliferation of endometrial
epithelial cells, since a PROK1-mediated decrease in cellular prolifer-
ation was prevented in PROKR1 Ishikawa cells transfected with
DKK1 siRNA or infected with adenovirus over-expressing
RCAN1-4. As this suggests that PROK1 can cause a decrease in the
proliferation of endometrial epithelial cells via DKK1 release; we pos-
tulate that this occurs through an inhibition of Wnt signalling. We
propose that this represents an important new function of PROK1
in the endometrium across the menstrual cycle, and that DKK1
secretion switches to become basal–basolateral in the uterine
glands at the time of implantation so as not to compromise blastocyst
development.
Furthermore, we demonstrate a role for PROK1 and DKK1 in med-
iating decidualization of the endometrial stroma. DKK1 expression is
known to be increased upon decidualization of human endometrial
stromal cells in culture (Kao et al., 2002; Tulac et al., 2006; Kane
et al., 2008). Here we have shown its levels to be elevated in ﬁrst tri-
mester decidua tissue, where it localizes primarily to the stromal com-
partment. Recently, PROK1 levels have also been shown to increase in
stromal cells decidualized in vitro (Salker et al., 2010; Tiberi et al.,
2010), and PROK1 is similarly increased in decidua tissue (Evans
et al., 2008). We have found that when the expression of either
DKK1 or PROK1 is knocked down in primary endometrial stromal
cells, there is a decrease in the expression of the markers of decidua-
lization IGFBP1, PRL and IL11 in response to a decidualizing stimulus.
Fluorescent microscopy also demonstrated that after knock down of
PROK1 or DKK1, primary stromal cells fail to adopt the characteristic
rounded cobble stone-like morphology indicative of decidualization,
but rather maintain the long spindle cell-type morphology observed
in control undecidualized stromal cells.
Previous studies have indicated the regulation of DKK1 (Tulac et al.,
2006) and PROK1 (Battersby et al., 2004) expression by progesterone
in the human endometrium. In the current study, progesterone and
cAMP in combination induced DKK1 expression in endometrial
stromal cells. However, knock down of PROK1 expression in endo-
metrial stromal cells reduces DKK1 expression and protein release
upon treatment with progesterone and cAMP, but does not abolish
it. Therefore, we propose that both DKK1 and PROK1 lie
downstream in the progesterone/cAMP signalling cascade, with
potential for DKK1 to be regulated by progesterone directly, and
indirectly via progesterone-mediated regulation of PROK1.
In conclusion, we have identiﬁed a novel signalling pathway whereby
PROK1 can induce the expression of DKK1 in the human endome-
trium and ﬁrst trimester decidua. We propose that via negative regu-
lation of cellular proliferation and decidualization, PROK1-mediated
DKK1 expression contributes to the generation of a receptive endo-
metrium. Dysregulation of PROK1-mediated expression of DKK1
may be a contributing factor to infertility and recurrent pregnancy loss.
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